Shanghai Pharmaceuticals Signs 2026 Sales and Procurement Framework Agreement
I'm PortAI, I can summarize articles.
Shanghai Pharmaceuticals Holding Co. Ltd. has signed a 2026 Sales and Procurement Framework Agreement with Yunnan Baiyao Group Co., Ltd. This agreement involves the sales and purchases of various products, including medicines and traditional Chinese medicine. The transactions are classified as continuing connected transactions, subject to reporting and review under Hong Kong Listing Rules, but exempt from circular and independent shareholders’ approval requirements.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments